Vesalius Research Center, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.
Basic Res Cardiol. 2010 Mar;105(2):169-79. doi: 10.1007/s00395-009-0077-4. Epub 2009 Dec 18.
Nitric oxide modulates the severity of myocardial ischemia-reperfusion (I/R) injury. We investigated whether cardioselective nitric oxide synthase 3 (NOS3) gene transfer could confer myocardial protection against I/R injury in pigs and examined potential molecular mechanisms. I/R injury was induced by balloon occlusion of the left anterior descending artery for 45 min followed by 4 or 72 h reperfusion. Hemodynamic and pathological changes were measured in pigs in the absence (n = 11) or presence of prior intracoronary retroinfusion of human NOS3 (AdNOS3, 5 x 10(10) PFU, n = 13) or control vector (AdRR5, 5 x 10(10) PFU, n = 11). Retrograde NOS3 gene transfer selectively increased NOS3 expression and NO bioavailability in the area at risk (AAR) without changing endogenous NOS isoform expression. At 4 h R, LV systolic (dP/dt(max)) and diastolic (dP/dt(min)) function was better preserved in AdNOS3- than in AdRR5-injected pigs (2,539 +/- 165 vs. 1,829 +/- 156 mmHg/s, and -2,781 +/- 340 vs. -2,062 +/- 292 mmHg/s, respectively, P < 0.05 for both). Myocardial infarct size (% AAR) was significantly smaller in AdNOS3 than in control and AdRR5 and associated with a significantly greater reduction in cardiac myeloperoxidase activity, a marker of neutrophil infiltration. The latter effects were sustained at 72 h R in a subset of pigs (n = 7). In the AAR, intercellular endothelial adhesion molecule-1 expression and cardiomyocyte apoptosis were significantly lower in AdNOS3. In conclusion, single myocardial NOS3 retroinfusion attenuates I/R injury, and causes a sustained reduction in myocardial infarct size and inflammatory cell infiltration. Gene-based strategies to increase NO bioavailability may have therapeutic potential in myocardial I/R.
一氧化氮调节心肌缺血再灌注(I / R)损伤的严重程度。我们研究了选择性心肌一氧化氮合酶 3(NOS3)基因转移是否可以赋予猪心肌对 I / R 损伤的保护作用,并检查了潜在的分子机制。通过气囊阻塞左前降支 45 分钟,然后再灌注 4 或 72 小时,诱导 I / R 损伤。在没有(n = 11)或存在先前冠状动脉内逆行输注人 NOS3(AdNOS3,5 x 10(10)PFU,n = 13)或对照载体(AdRR5,5 x 10(10)PFU,n = 11)的情况下,测量猪的血流动力学和病理变化。逆行 NOS3 基因转移选择性地增加了风险区域(AAR)中的 NOS3 表达和 NO 生物利用度,而不改变内源性 NOS 同工型表达。在 4 小时 R 时,与 AdRR5 注射的猪相比,AdNOS3 注射的猪的 LV 收缩(dP / dt(max))和舒张(dP / dt(min))功能更好地保存(分别为 2,539 +/- 165 对 1,829 +/- 156 mmHg / s,-2,781 +/- 340 对-2,062 +/- 292 mmHg / s,两者均 P <0.05)。与对照组和 AdRR5 相比,AdNOS3 的心肌梗塞面积(% AAR)明显较小,并且与中性粒细胞浸润标志物心脏髓过氧化物酶活性的显著降低相关。在一组猪中(n = 7),在 72 小时 R 时,这种影响持续存在。在 AAR 中,细胞间内皮细胞粘附分子-1表达和心肌细胞凋亡在 AdNOS3 中明显降低。总之,单一心肌 NOS3 逆行输注可减轻 I / R 损伤,并导致心肌梗塞面积和炎症细胞浸润的持续减少。增加 NO 生物利用度的基因治疗策略可能在心肌 I / R 中具有治疗潜力。